Table 1.
Main characteristics of the selected studies.
| Study | Year | Trial Phase | Country | N | Cancer Type | Treatment | ICI Dose | Intervention Period | OS | PFS | Toxicity ≥Grade 3 (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hirva Mamdani | 2021 | II | US | 37 | rE/rGEJ AC | Sequential. Neoadj CRT: - standard RT dose - FP or TC QW Surgery: -R0 resection (Pathological residual tissue) |
Durvalumab 1500 mg IV Q4W |
13 doses (12 months), or until unacceptable toxicities or disease recurrence. | NR | NR | 10 (27%) |
|
| Kelly | 2021 | III | US | 532 | rE/rGEJ | Sequential. Neoadj CRT: <41.4Gy 12% <40Gy 1% 40-41.4Gy 11% 41.4-50.4Gy 64% >50.4 Gy 18% NA 6% TC 73% FP 14% Other 12% Surgery: -R0 resection (Pathological residual tissue) |
Nivolumab 240 mg IV Q2W- 480mg IV Q4W |
240 mg every 2 weeks for 16 weeks, followed by 480 mg every 4 weeks (12 months) |
mOS 22.4 months |
NR | 183 (34%) |
|
| Zhang | 2021.06 | I/Ib | CN | 19 | Locally advanced ESCC | Concurrent and Sequential. RT: - 60 Gy (2.0 Gy/fraction) |
Camrelizumab 200 mg IV Q2W |
From radiotherapy onset for up to 32 weeks |
mOS 16.7 months |
mPFS 11.7 months |
10 (53%) |
|
| Zhang | 2021.09 | 1b | CN | 20 | Locally advanced ESCC |
Concurrent and Sequential. CRT: - RT: 60 Gy (2.0 Gy/fraction) - DP QW DTX 25mg/m2 CDDP 25mg/m2 |
Camrelizumab 200 mg IV Q2W |
From radiotherapy onset for up to 32 weeks |
1-year OS: 85% 2-Year OS: 69.6% |
1-year PFS: 80% 1- Year PFS: 69.6% |
9 (45%) |
|
| Li | 2020 | II | CN | 20 | rESCC | Concurrent. Neoadj CRT: - RT: 41.4 Gy (1.8 Gy/fraction) -TC QW: CBDCA AUC=2 PTX 50mg/m2 Concurrent and Sequential. Surgery: -Within 4-6 weeks post-surgery |
Pembrolizumab 2mg/kg IV Q3W |
2 doses | NR | NR | 13 (65%) |
|
| Ende | 2021 | II | NL | 40 | rEAC | Neoadj CRT: - RT: 41.4 Gy (1.8 Gy/fraction) -TC QW: CBDCA AUC=2 PTX 50mg/m2 Surgery: -Within 14-16 weeks post-surgery |
Atezolizumab 1200 mg IV Q3W |
5 doses | mOS 29.7 months |
mPFS 19.4 months |
16 (40%) |
|
N, Number of patients; ICIs, Immune checkpoint inhibitors; OS, Overall survival; PFS, Progression free survival; rE, Resectable esophageal cancer; rGEJ, Resectable gastroesophageal junction cancer; AC, Adenocarcinoma; Neoadj, Neoadjuvant; CRT, Chemoradiotherapy; RT, Radiotherapy; FP, 5-Fluorouracil plus cisplatin; TC, Paclitaxel plus carboplatin; QW, Once a week; IV, Intravenous; Q4W, Every 4 weeks; NR, Not reported; ESCC, Esophageal squamous cell carcinoma; Q2W, Every 2 weeks; mOS, Median overall survival; mPFS, Median progression-free survival; rESCC, Resectable esophageal squamous cell carcinoma; CBDCA, Carboplatin; AUC, Area under the curve; PTX, Paclitaxel; Q3W, Ever 3 weeks; DP, Docetaxel plus cisplatin; DTX, Docetaxel; CDDP, Cisplatin; rEAC, Esophageal adenocarcinoma.